About Us
ClinomicsAI is transforming the future of ophthalmology and precision medicine.
Founded by leading surgeon-scientists Dr. David Almeida and Dr. Vinit Mahajan, our platform harnesses liquid biopsy proteomics and artificial intelligence to trace disease activity down to the cellular level—non-invasively and in real time.
We are redefining what’s possible in the diagnosis, monitoring, and treatment of eye diseases through high-resolution proteomic profiling and machine learning tools. From macular degeneration to Parkinson’s disease, we are revealing the molecular fingerprints of aging and disease where it matters most—inside the living eye.